Skip to main content
SpringerLink
Log in
Book cover

Allogeneic Stem Cell Transplantation pp 11–27Cite as

Full Intensity and Reduced Intensity Allogeneic Transplantation in AML

  • Chapter
  • First Online:

  • 1470 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

Acute myeloid leukemia (AML) is now the commonest indication for allogeneic stem cell transplantation (SCT) in adults [1]. This reflects the continued inability of conventional chemotherapeutic regimens to deliver long-term disease-free survival in most adults -- a failure which is particularly marked in patients over the age of 50 years whose outcome has barely improved in the last three decades [2, 3]. Whilst it has been clear for a number of years that the allogeneic transplantation delivers a more potent anti-leukemic effect than chemotherapy, the toxicity of myeloablative conditioning regimens has precluded its use in precisely the group of patients who urgently need new therapeutic options. However, the recent demonstration that the use of reduced intensity conditioning regimens substantially reduces the transplant-related mortality (TRM) has provided the prospect of delivering a potentially curative graft-versus-leukemia (GVL) effect in patients in whom it was previously contraindicated [4, 5]. Importantly, this has provided a new treatment option for a group of patients whose outcome if treated with chemotherapy alone would be very poor.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A (2006) EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 37(12):1069-1085

    Article  PubMed  CAS  Google Scholar 

  2. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K et al (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108(10):3280-3288

    Article  PubMed  CAS  Google Scholar 

  3. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98(5):1312-1320

    Article  PubMed  CAS  Google Scholar 

  4. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al (1997) Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89(12):4531-4536

    PubMed  CAS  Google Scholar 

  5. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97(11):3390-3400

    Article  PubMed  CAS  Google Scholar 

  6. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7):730-737

    Article  PubMed  CAS  Google Scholar 

  7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-1037

    Article  PubMed  CAS  Google Scholar 

  8. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al (2006) A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108(10):3262-3270

    Article  PubMed  CAS  Google Scholar 

  9. Harousseau JL, Lancet JE, Reiffers J, Lowenberg B, Thomas X, Huguet F et al (2007) A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 109(12):5151-5156

    Article  PubMed  CAS  Google Scholar 

  10. Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL et al (2007) A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109(4):1387-1394

    Article  PubMed  CAS  Google Scholar 

  11. Bullinger L, Valk PJ (2005) Gene expression profiling in acute myeloid leukemia. J Clin Oncol 23(26):6296-6305

    Article  PubMed  CAS  Google Scholar 

  12. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM et al (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16) 1617-1628

    Google Scholar 

  13. Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR (2002) Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1(1):63-74

    Article  PubMed  CAS  Google Scholar 

  14. Frohling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 23(26):6285-6295

    Article  PubMed  CAS  Google Scholar 

  15. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C (2006) Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol 7(10):1048-1056

    Article  PubMed  CAS  Google Scholar 

  16. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98(8):2301-2307

    Article  PubMed  CAS  Google Scholar 

  17. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99(25):16220-16225

    Article  PubMed  CAS  Google Scholar 

  18. Bacigalupo A, Vitale V, Corvo R, Barra S, Lamparelli T, Gualandi F et al (2000) The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol 108(1):99-104

    Article  PubMed  CAS  Google Scholar 

  19. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al (1991) Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77(7):1423-1428

    PubMed  CAS  Google Scholar 

  20. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al (2000) Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 95(5):1572-1579

    PubMed  CAS  Google Scholar 

  21. Greiner J, Dohner H, Schmitt M (2006) Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91(12):1653-1661

    PubMed  CAS  Google Scholar 

  22. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E et al (2007) Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 110(6):1924-1932

    Article  PubMed  CAS  Google Scholar 

  23. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al (2002) CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100(6):2132-2137

    Article  PubMed  CAS  Google Scholar 

  24. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA et al (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100(5):2742-2747

    Article  PubMed  CAS  Google Scholar 

  25. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A et al (2006) Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Blood 108(13):4109-4117

    Article  PubMed  CAS  Google Scholar 

  26. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C et al (2006) High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24(10):1507-1515

    Article  PubMed  CAS  Google Scholar 

  27. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al (2004) Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101(38):13885-13890

    Article  PubMed  CAS  Google Scholar 

  28. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19(13):3244-3254

    PubMed  CAS  Google Scholar 

  29. Xue SA, Gao L, Hart D, Gillmore R, Qasim W, Thrasher A et al (2005) Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 106(9):3062-3067

    Article  PubMed  CAS  Google Scholar 

  30. Wheatley K (2002) Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - a statistician’s view. Br J Haematol 118(2):351-356

    Article  PubMed  Google Scholar 

  31. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 90(8):2978-2986

    PubMed  CAS  Google Scholar 

  32. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al (2007) Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: Benefits for whom? Blood 109(9):3658-3666

    Article  PubMed  CAS  Google Scholar 

  33. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F et al (2005) Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat long-term analysis of the BGMT experience. J Clin Oncol 23(30):7676-7684

    Article  PubMed  Google Scholar 

  34. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial. Br J Haematol 118(2):385-400

    Article  PubMed  Google Scholar 

  35. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102(4):1232-1240

    Article  PubMed  CAS  Google Scholar 

  36. Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL (2007) Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. Biol Blood Marrow Transplant 13(6):724-733

    Article  PubMed  CAS  Google Scholar 

  37. Burnett AK (2002) Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? - an adult treater’s view. Br J Haematol 118(2):357-364

    Article  PubMed  Google Scholar 

  38. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106(12):3740-3746

    Article  PubMed  Google Scholar 

  39. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al (2007) The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):2776-2784

    Article  PubMed  Google Scholar 

  40. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M et al (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90(6):2465-2470

    PubMed  CAS  Google Scholar 

  41. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23(9):1969-1978

    Article  PubMed  Google Scholar 

  42. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M et al (1996) Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: A retrospective single-center study. Ann Hematol 72(4):216-222

    Article  PubMed  CAS  Google Scholar 

  43. Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH et al (1996) Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia 10(1):13-19

    PubMed  CAS  Google Scholar 

  44. Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM et al (2007) Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110(1):409-417

    Article  PubMed  CAS  Google Scholar 

  45. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D et al (2000) Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 96(4):1254-1258

    PubMed  CAS  Google Scholar 

  46. Fung HC, Stein A, Slovak M, O’Donnell MR, Snyder DS, Cohen S et al (2003) A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 9(12):766-771

    Article  PubMed  CAS  Google Scholar 

  47. Oyekunle AA, Kroger N, Zabelina T, Ayuk F, Schieder H, Renges H et al (2006) Allogeneic stem-cell transplantation in patients with refractory acute leukemia: A long-term follow-up. Bone Marrow Transplant 37(1):45-50

    PubMed  CAS  Google Scholar 

  48. Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I et al (2005) Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11(2):108-114

    Article  PubMed  Google Scholar 

  49. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W et al (1992) Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80(4):1090-1093

    PubMed  CAS  Google Scholar 

  50. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP et al (1992) Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: A report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 79(10):2578-2582

    PubMed  CAS  Google Scholar 

  51. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E et al (1994) Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84(6):2036-2043

    PubMed  CAS  Google Scholar 

  52. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP et al (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: A randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the French Society of Bone Marrow. Blood 85(8):2263-2268

    PubMed  CAS  Google Scholar 

  53. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al (1994) A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 83(9):2723-2730

    PubMed  CAS  Google Scholar 

  54. Socie G, Clift RA, Blaise D, Devergie A, Ringden O, Martin PJ et al (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 98(13):3569-3574

    Article  PubMed  CAS  Google Scholar 

  55. Ringden O, Remberger M, Ruutu T, Nikoskelainen J, Volin L, Vindelov L et al (1999) Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 93(7):2196-2201

    PubMed  CAS  Google Scholar 

  56. Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA et al (2002) Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119(4):1115-1124

    Article  PubMed  CAS  Google Scholar 

  57. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G (1997) High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 20(11):909-913

    Article  PubMed  CAS  Google Scholar 

  58. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al (1997) Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8):3055-3060

    PubMed  CAS  Google Scholar 

  59. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al (2002) Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100(4):1201-1207

    Article  PubMed  CAS  Google Scholar 

  60. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D et al (2007) Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 13(1):56-64

    Article  PubMed  CAS  Google Scholar 

  61. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al (2007) Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 110(4):1379-1387

    Article  PubMed  CAS  Google Scholar 

  62. Kim SE, Lee JH, Choi SJ, Ryu SG, Lee KH (2005) Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: A retrospective comparison of oral versus intravenous busulfan. Haematologica 90(2):285-286

    PubMed  CAS  Google Scholar 

  63. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F et al (1998) T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease. Blood 91(3):1083-1090

    PubMed  CAS  Google Scholar 

  64. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344(3):175-181

    Article  PubMed  CAS  Google Scholar 

  65. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O et al (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 22(24):4872-4880

    Article  PubMed  Google Scholar 

  66. Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS et al (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 108(2):408-414

    Article  PubMed  CAS  Google Scholar 

  67. Nakamura R, Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R et al (2001) Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 115(1):95-104

    Article  PubMed  CAS  Google Scholar 

  68. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al (2001) Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98(6):1695-1700

    Article  PubMed  CAS  Google Scholar 

  69. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A et al (2000) Unrelated donor marrow transplantation for acute myeloid leukemia: An update of the Seattle experience. Bone Marrow Transplant 26(4):397-404

    Article  PubMed  CAS  Google Scholar 

  70. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351(22):2276-2285

    Article  PubMed  CAS  Google Scholar 

  71. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE (2003) Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 102(5):1915-1919

    Article  PubMed  CAS  Google Scholar 

  72. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756-763

    PubMed  CAS  Google Scholar 

  73. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplant. Blood 104(3):865-872

    Article  PubMed  Google Scholar 

  74. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al (2006) Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24(3):444-453

    Article  PubMed  CAS  Google Scholar 

  75. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ et al (2005) Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 104(9):1931-1938

    Article  PubMed  CAS  Google Scholar 

  76. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 102(2):470-476

    Article  PubMed  CAS  Google Scholar 

  77. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al (2005) Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23(36):9387-9393

    Article  PubMed  CAS  Google Scholar 

  78. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al (2005) Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5728-5738

    Article  PubMed  Google Scholar 

  79. Mohty M, de Lavallade H, Ladaique P, Faucher C, Vey N, Coso D et al (2005) The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: A donor vs no donor comparison. Leukemia 19(6):916-920

    Article  PubMed  CAS  Google Scholar 

  80. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al (2004) Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-864

    Article  PubMed  Google Scholar 

  81. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF (2007) Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 92(7):1004-1006

    Article  PubMed  Google Scholar 

  82. Dominietto A, Pozzi S, Miglino M, Albarracin F, Piaggio G, Bertolotti F et al (2007) Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 109(11):5063-5064

    Article  PubMed  CAS  Google Scholar 

  83. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100(9):3108-3114

    Article  PubMed  CAS  Google Scholar 

  84. Peggs KS, Thomson K, Hart DP, Geary J, Morris EC, Yong K et al (2004) Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 103(4):1548-1556

    Article  PubMed  CAS  Google Scholar 

  85. Kolb HJ, Schmid C, Buhmann R, Tischer J, Ledderose G (2005) DLI: Where are we know? Hematology 10(Suppl 1):115-116

    Article  PubMed  Google Scholar 

  86. Tse WW, Zang SL, Bunting KD, Laughlin MJ (2008) Umbilical cord blood transplantation in adult myeloid leukemia. Bone Marrow Transplant 41(5):465-472

    Article  PubMed  CAS  Google Scholar 

  87. Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M et al (2008) Reduced-intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 14(3):282-289

    Article  PubMed  CAS  Google Scholar 

  88. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23(24):5675-5687

    Article  PubMed  Google Scholar 

  89. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al (2006) Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108(3):1092-1099

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Clinical Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK

    Charles Craddock

Authors
  1. Charles Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University Hospitals Case Medical Center, Cleveland, OH, USA

    Hillard M. Lazarus

  2. Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Craddock, C. (2010). Full Intensity and Reduced Intensity Allogeneic Transplantation in AML. In: Lazarus, H.M., Laughlin, M.J. (eds) Allogeneic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-478-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-478-0_2

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-33-6

  • Online ISBN: 978-1-59745-478-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation